Oppenheimer Sticks to Its Buy Rating for Perspective Therapeutics (CATX)
I'm PortAI, I can summarize articles.
Oppenheimer analyst Jeff Jones reiterated a Buy rating for Perspective Therapeutics (CATX) with a price target of $13.00. UBS also maintained a Buy rating with a $7.00 target. Jones, a 3-star analyst with a 2.9% average return, focuses on the Healthcare sector. The report highlights investment insights and research tools available at a discount during TipRanks' Black Friday Sale.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments